How does your service ensure accurate identification of antibody isotypes?

Our service employs a range of rigorous and validated techniques to guarantee precise isotype identification. We utilize methods such as ELISAs with isotype-specific antibodies, flow cytometry for single-cell analysis, and, when necessary, more specialized techniques like mass spectrometry. Each method is performed by experienced technicians, and results are confirmed through multiple quality control steps to eliminate any ambiguity and ensure the highest level of accuracy in determining the antibody's class and subclass.

What are the normal phases involved in your hybridoma isotype switching process?

Our hybridoma isotype switching process generally involves several key steps. Initially, we design and construct vectors that carry the gene encoding the desired isotype's constant region. Subsequently, we introduce these vectors into the hybridoma cells using efficient gene transfer techniques, such as electroporation or viral transduction. Following this, we apply selective pressure to isolate cells that have successfully undergone the isotype switch. Finally, we rigorously screen and characterize the resulting clones to confirm the isotype change and verify that the antibody retains its original antigen-binding specificity.

Can you switch antibody isotypes for any species, or are there limitations?

Our isotype switching capabilities cover a broad range of species, including but not limited to mouse, rat, and human. We have established protocols and optimized vectors for the most commonly used species in antibody research and therapeutic development. While our primary focus is on these species, we also have the expertise and resources to explore isotype switching in other species, though this may require some additional development and optimization. We invite clients to approach us with particular requests.

How does isotype switching affect the antigen-binding specificity and affinity of the antibody?

Isotype switching alters the antibody's constant region, which determines its effector functions, while leaving the variable region, responsible for antigen binding, unchanged. Therefore, successful isotype switching should not affect the antibody's original antigen-binding affinity or specificity. Our switching protocols are designed to preserve the variable region's integrity, and we conduct thorough testing, including binding assays, to confirm that the antibody maintains its ability to bind to the target antigen post-switch.

How do you ensure the stability and long-term productivity of the isotype-switched hybridoma cell lines?

Ensuring the stability and long-term productivity of isotype-switched hybridoma cell lines is a priority for our service. After the switching process, we employ rigorous selection and cloning strategies to isolate stable cell lines that consistently produce the desired antibody isotype. We also conduct extensive characterization, including growth curve analysis and antibody production monitoring, to assess the long-term viability and productivity of the selected clones. Furthermore, we offer cell banking services to preserve these valuable cell lines for future use.

What support do you provide to clients after the completion of the isotype switching project?

Our commitment to client satisfaction extends beyond the completion of the project. We give continuing support to our clients, including aid with data interpretation, troubleshooting, and further antibody development. We give detailed final reports summarizing the project's results, and our team of experts is always accessible to answer any questions or provide additional guidance. We strive to build long-term relationships with our clients and serve as a valuable resource for all their antibody engineering needs.

Hybridoma Isotype Identification & Switching Service

Overview Service Importance Features FAQ

Creative Biolabs provides world-class hybridoma isotype identification and switching services, providing comprehensive solutions for antibody characterization and engineering based on cutting-edge technology and extensive expertise. With our services, customers can gain a deeper understanding of their antibodies' functions, optimize their development processes, and expand the potential of their antibody-based applications.

Overview of Isotype Identification and Switching

The immunoglobulin (Ig) isotype, or class, is intrinsically determined by the constant region of the Ig gene, which constitutes the antibody's Fc portion. This Fc region is pivotal, as the specific function of an antibody isotype is directly dictated by its selective binding to Fc receptor molecules expressed on various immune effector cells. Consequently, distinct isotype expression patterns serve as critical indicators, reflecting the diverse maturation stages characteristic of a B lymphocyte. Initially, naive B cells, characterized by their unmutated variable genes, co-express IgM and IgD isotypes primarily through a sophisticated process of alternative splicing. However, the subsequent expression of other antibody isotypes, such as the human IgG1-4, IgA1-2, and IgE subclasses, is stringently dependent upon a meticulously regulated process known as class-switch recombination (CSR), which is triggered following initial antigen exposure.

CSR represents a profoundly fundamental biological mechanism within the humoral immune response. Its core function is to facilitate a B cell's irreversible transition from producing one Ig isotype to another. A classic example is the switch from IgM production to IgG following the primary encounter with an antigen during immunization. Crucially, this intricate process involves a precise genetic rearrangement that specifically alters the constant region of the antibody heavy chain while rigorously preserving the variable region. This preservation ensures that the antigen specificity of the antibody remains entirely unaltered. Therefore, while the antibody maintains its original high affinity for the same antigens, it simultaneously acquires the capacity to interact with a diverse array of effector molecules. This remarkable adaptation allows the antibody to modulate its downstream immune functions, leading to different immunological outcomes tailored to the specific nature of the pathogen or immune challenge.

Fig.1 Procedure for mouse IgH locus rearrangement. (Dauba and Ahmed, 2021) Fig.1 Rearranged the mouse IgH locus.¹

Hybridoma Isotype Identification and Switching Service

Creative Biolabs provides isotype identification and switches among the five main Ig classes, in which IgG1, IgG2, and IgG4 have been used as engineering therapeutic antibodies. More recently, IgA, IgM, and IgE have been used to adjust the recombinant molecules better to the targeted application (e.g. regarding half-life, effector functions, etc.). Notably, we can produce chimeric antibodies with different Fc domains using our unique cloning cassettes for all antibody classes and subclasses of the human (IgA, IgD, IgM, IgE, IgG1, IgG2, IgG3, and IgG4) and mouse (IgA, IgD, IgM, IgE, IgG1, IgG2a, IgG2b, and IgG3) species.

Cloning Vectors Available:

Species	Heavy Chain	Light Chain
Human	IgG1, IgG2, IgG3, IgG4	Igκ, Igλ2
Mouse	IgG1, IgG2a, IgG2b, IgG3	Igκ, Igλ1, Igλ2
Rabbit	IgG1	Igκ1, Igκ2, Igλ
Rat	IgG2b	Igκ, Igλ

Importance of Hybridoma Isotype Identification and Switching

Isotype identification is a fundamental step in antibody characterization, providing critical insights into its biological function. The isotype of an antibody directly influences its effector mechanisms, including complement activation, ADCC, and binding to Fc receptors on immune cells. Knowing the isotype allows researchers to select the most appropriate antibody for a specific application. For example, if the goal is to elicit a strong ADCC response, an IgG isotype might be preferred. Furthermore, accurate isotype identification is essential for developing reliable immunoassays and ensuring the quality control of antibody-based products.

Isotype switching plays a pivotal role in expanding the therapeutic potential of monoclonal antibodies. By changing the isotype of an antibody, it is possible to modify its effector functions and pharmacokinetic properties, thereby optimizing its efficacy and safety in clinical applications. For instance, switching an antibody to an isotype with a longer half-life can improve its therapeutic efficacy by reducing the frequency of administration. Additionally, isotype switching can be used to generate antibodies with enhanced ADCC activity for cancer immunotherapy or to create antibodies that are better suited for mucosal immunity.

Features of Our Service

Quick turnaround times
Repeatability and high reliability of experimental results
Precise identification and comprehensive profiling of antibody isotypes
Detailed reporting for insightful analysis
Customized isotype switching and reliable switching plan
Expert support for optimized experimental design

FAQ

Q: How does your service ensure accurate identification of antibody isotypes?
A: Our service employs a range of rigorous and validated techniques to guarantee precise isotype identification. We utilize methods such as ELISAs with isotype-specific antibodies, flow cytometry for single-cell analysis, and, when necessary, more specialized techniques like mass spectrometry. Each method is performed by experienced technicians, and results are confirmed through multiple quality control steps to eliminate any ambiguity and ensure the highest level of accuracy in determining the antibody's class and subclass.
Q: What are the normal phases involved in your hybridoma isotype switching process?
A: Our hybridoma isotype switching process generally involves several key steps. Initially, we design and construct vectors that carry the gene encoding the desired isotype's constant region. Subsequently, we introduce these vectors into the hybridoma cells using efficient gene transfer techniques, such as electroporation or viral transduction. Following this, we apply selective pressure to isolate cells that have successfully undergone the isotype switch. Finally, we rigorously screen and characterize the resulting clones to confirm the isotype change and verify that the antibody retains its original antigen-binding specificity.
Q: Can you switch antibody isotypes for any species, or are there limitations?
A: Our isotype switching capabilities cover a broad range of species, including but not limited to mouse, rat, and human. We have established protocols and optimized vectors for the most commonly used species in antibody research and therapeutic development. While our primary focus is on these species, we also have the expertise and resources to explore isotype switching in other species, though this may require some additional development and optimization. We invite clients to approach us with particular requests.
Q: How does isotype switching affect the antigen-binding specificity and affinity of the antibody?
A: Isotype switching alters the antibody's constant region, which determines its effector functions, while leaving the variable region, responsible for antigen binding, unchanged. Therefore, successful isotype switching should not affect the antibody's original antigen-binding affinity or specificity. Our switching protocols are designed to preserve the variable region's integrity, and we conduct thorough testing, including binding assays, to confirm that the antibody maintains its ability to bind to the target antigen post-switch.
Q: How do you ensure the stability and long-term productivity of the isotype-switched hybridoma cell lines?
A: Ensuring the stability and long-term productivity of isotype-switched hybridoma cell lines is a priority for our service. After the switching process, we employ rigorous selection and cloning strategies to isolate stable cell lines that consistently produce the desired antibody isotype. We also conduct extensive characterization, including growth curve analysis and antibody production monitoring, to assess the long-term viability and productivity of the selected clones. Furthermore, we offer cell banking services to preserve these valuable cell lines for future use.
Q: What support do you provide to clients after the completion of the isotype switching project?
A: Our commitment to client satisfaction extends beyond the completion of the project. We give continuing support to our clients, including aid with data interpretation, troubleshooting, and further antibody development. We give detailed final reports summarizing the project's results, and our team of experts is always accessible to answer any questions or provide additional guidance. We strive to build long-term relationships with our clients and serve as a valuable resource for all their antibody engineering needs.

As one of the most competitive biotechnology companies in the word, creative Biolabs has extensive expertise and experience to provide you with custom hybridoma and recombinant antibody development services. Our services are tailored for each project to ensure that the objectives are met or exceeded. For more information, please do not hesitate to contact us for more details.

Reference

Dauba, Audrey, and Ahmed Amine Khamlichi. "Long-range control of class switch recombination by transcriptional regulatory elements." Frontiers in Immunology 12 (2021): 738216.
Distributed under Open Access license CC BY 4.0, without modification.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: